0001437749-18-012122.txt : 20180620 0001437749-18-012122.hdr.sgml : 20180620 20180620134009 ACCESSION NUMBER: 0001437749-18-012122 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180618 ITEM INFORMATION: Other Events FILED AS OF DATE: 20180620 DATE AS OF CHANGE: 20180620 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aeon Global Health Corp. CENTRAL INDEX KEY: 0000885074 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 141673067 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-20190 FILM NUMBER: 18909219 BUSINESS ADDRESS: STREET 1: 2225 CENTENNIAL DRIVE CITY: GAINESVILLE STATE: 2Q ZIP: 30504 BUSINESS PHONE: 888-661-0225 MAIL ADDRESS: STREET 1: 2225 CENTENNIAL DRIVE CITY: GAINESVILLE STATE: 2Q ZIP: 30504 FORMER COMPANY: FORMER CONFORMED NAME: AUTHENTIDATE HOLDING CORP DATE OF NAME CHANGE: 20010327 FORMER COMPANY: FORMER CONFORMED NAME: BITWISE DESIGNS INC DATE OF NAME CHANGE: 19930328 8-K 1 aghc20180620_8k.htm FORM 8-K aghc20180620_8k.htm

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): June 18, 2018

 

AEON GLOBAL HEALTH CORP.

(Exact name of registrant as specified in its charter)

 

COMMISSION FILE NUMBER:  0-20190

 

DELAWARE

14-1673067

(State or other jurisdiction of incorporation or organization)

(I.R.S. Employer Identification No.)

 

 

2225 Centennial Drive

Gainesville, GA 30504

(Address and zip code of principal executive offices)

 

1-(888) 661-0225
(Registrant’s telephone number, including area code

 

                                                                                    

(Former Name, if Changed Since Last Report)

 

CHECK THE APPROPRIATE BOX BELOW IF THE FORM 8-K FILING IS INTENDED TO SIMULTANEOUSLY SATISFY THE FILING OBLIGATION OF THE REGISTRANT UNDER ANY OF THE FOLLOWING PROVISIONS:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

1
 

 

Item 8.01

Other Events.

 

On June 18, 2018, the Board of Directors of Aeon Global Health Corp. (the “Company”) declared a dividend on its outstanding shares of Series D Convertible Preferred Stock in the aggregate amount of $921,965 and a dividend on the outstanding shares of its Series E Convertible Preferred Stock in the aggregate amount of $47,979. The dividends will be payable on June 30, 2018. The Board determined to pay the dividends on the Series D Preferred Stock through the issuance of additional shares of Common Stock, in accordance with the terms and conditions of the Certificate of Designations, Preferences and Rights and Number of Shares of Series D Convertible Preferred Stock. The shares of Common Stock to be issued to the holders of the Series D Preferred Stock will be issued pursuant to the exemption from registration under Section 4(a)(2) of the Securities Act of 1993, as amended.

 

2
 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

 

 

AEON GLOBAL HEALTH CORP.
   

 

 

 

By: /s/ Michael J. Poelking 

 

Name: Michael J. Poelking

 

Title:   Chief Financial Officer 

 Date:   June 20, 2018

  

 

 

3